Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.48 |
| ▸ | BTK | Q06187 | 19/20 | 0.48 |
| ▸ | BLK | P51451 | 3/20 | 0.47 |
| ▸ | BMX | P51813 | 4/20 | 0.46 |
| ▸ | TEC | P42680 | 3/20 | 0.46 |
| ▸ | TXK | P42681 | 2/20 | 0.46 |
| ▸ | LYN | P07948 | 2/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.46 |
| ▸ | ITK | Q08881 | 2/20 | 0.46 |
| ▸ | HCK | P08631 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.46 |
| ▸ | LATS1 | O95835 | 1/20 | 0.46 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655271 | 0.97 | EGFR (0.48) | EGFRBTKBLKBMXTEC | |
| SCHEMBL16655734 | 0.91 | RET (0.43) | EGFRBTKRETKDR | |
| SCHEMBL23917225 | 0.90 | EGFR (0.44) | EGFRBTKBLKBMXTEC | |
| SCHEMBL16655803 | 0.89 | PIK3CD (0.49) | EGFRBTKFGFR2RETKDR | |
| SCHEMBL16655543 | 0.89 | RET (0.43) | EGFRBTKRETKDR | |
| SCHEMBL16655736 | 0.88 | PIK3CD (0.49) | EGFRBTKFGFR2RETKDR | |
| SCHEMBL16655372 | 0.86 | RET (0.59) | EGFRFGFR2ITKSRCABL1 | |
| SCHEMBL16655696 | 0.85 | RET (0.54) | BTKLYNNUDT14LCKRET | |
| SCHEMBL16655897 | 0.83 | RET (0.54) | BTKLYNNUDT14LCKRET | |
| SCHEMBL16656024 | 0.83 | BTK (0.44) | EGFRBTKBLKBMXTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | claimed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | claimed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | EGFR 828/4885BTK 1/4885BLK 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.